U.S. Pat. Appln. Serial No.: 10/561,055 Group Art Unit No.: 1621

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application.

Listing of Claims:

- 1. (Cancelled).
- 2. (Previously Presented). A compound of formula (la):

wherein:

R¹⁰ represents H or C₁₋₆ alkyl;

R¹² represents H, halo, CF₃, cyano, OCF₃, nitro, OR¹³, SR¹³, COR¹³ or C₁₋₆ alkyl;

R¹³ represents C₁₋₆ alkyl or C₁₋₄alkylaryl;

and physiologically functional derivatives thereof.

- 3. (Cancelled).
- 4. (Cancelled).
- 5. (Cancelled).
- 6. (**Previously Presented**). A pharmaceutical composition comprising a compound of claim 2, and pharmaceutically acceptable carriers or diluents.

U.S. Pat. Appln. Serial No.: 10/561,055 Group Art Unit No.: 1621

- (Currently Amended). A process for preparation of compounds of formula (Ia) of claim 2, which comprises:
- (A) reacting a compound of formula (II):

$$L-Q$$
 N R^2 (II)

wherein:

R2 is SO2R10, wherein R10 is as defined in claim 2;

Q is phenyl:

X is CO₂H; and

L represents a leaving group,

with a reagent suitable to introduce phenyl optionally substituted by R¹², wherein R¹² is as defined in claim 2; or a compound of formula (IV);

(H) reacting a compound of formula (VI)

$$R^1$$
Z Q N H (VI)

or a protected derivative thereof, wherein:

R¹ is phenyl optionally substituted by R¹², wherein R¹² us as defined in claim 2.

Z is a bond.

Q is phenyl and

X is CO₂H

with a reagent suitable to introduce the group $\underline{SO_2R^{10}}$ $\underline{CO_2H}$, wherein $\underline{R^{10}}$ is as defined in claim 2; or

- (J) carrying out a process selected from processes (A) to (H) followed by interconversion of one or more functional groups.
- 8.(Currently Amended). The pharmaceutical composition according to claim 6 further comprising one or more therapeutic agents, selected from anti-inflammatory agents, NSAIDs. beta adrenergic agents and anti-infective agents, wherein:

U.S. Pat. Appln. Serial No.: 10/561,055 Group Art Unit No.: 1621

the anti-inflammatory agents are selected from corticosteroids selected from fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide);

the NSAIDs are selected from sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, CCR-3 antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists;

the beta adrenergic agents are selected from salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof; or

the anti-infective agents are selected from antibiotics or antivirals.